Don’t forget treatment on World Hepatitis Day
July 28, 2015—The prohibitive price of hepatitis C virus medications will result in needless deaths if we don’t act now
On World Hepatitis Day 2015, as the World Health Organization (WHO) emphasizes prevention, the International Treatment Preparedness Coalition (ITPC) and Treatment Action Group (TAG) urge pharmaceutical companies and the governments of middle-income countries (MICs) to act now to facilitate access to treatment for all people with hepatitis C virus (HCV), to avoid needless deaths from HCV complications and to prevent new infections.
Research Toward a Cure
July 27, 2015 – A listing of clinical trials and observational studies related to the research effort to cure HIV infection.
2015 Pipeline Report
July 17, 2015 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Washington Blade Op-Ed: D.C. AIDS plan ambitious but must include community
July 10, 2015 – By Kenyon Farrow – Could D.C. be the next place that declares a bold plan for ending the HIV epidemic in just a few years? New York Gov. Andrew Cuomo was the first governor to announce such an effort. Now it appears that Mayor Muriel Bowser wants to make this a priority in her first term. But while I applaud the mayor for taking on this ambitious (yet achievable) goal, she needs to make the community part of the process of conceiving, developing, and implementing this new plan.
Public Health Groups Sue FDA For Disclosure of Clinical Trial Data for Costly Hep C Drugs
June 25, 2015, New Haven, Connecticut – Treatment Action Group (TAG) and the Global Health Justice Partnership (GHJP) have filed a federal lawsuit to obtain access to the information that Gilead Sciences submitted to the FDA to obtain approval of two new—and extremely expensive—hepatitis C drugs, Sovaldi (sofosbuvir) and Harvoni (sofosvubir/ledipasvir). Hepatitis C affects at least 3 million people in the United States. Sovaldi and Harvoni significantly improve cure rates, but initial pricing was unprecedented: $84,000 and $94,500 for a 12-week course of treatment, respectively.
Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan
June 24, 2015 – An objective of the National HIV/AIDS Strategy (NHAS), released by the White House in July 2010, is to lower the annual number of new infections in the United States by 25 percent by the end of 2015. Yet it is unclear if we will succeed in meeting this arguably unambitious target: 36,400 estimated new infections in 2015, compared with the 48,600 new infections estimated for the baseline year of 2006.
NYTimes Op-Ed: Don’t Weaken the F.D.A.’s Drug Approval Process
By Gregg Gonsalves, Mark Harrington, and David A. Kessler
June 11, 2015 – During the early days of the AIDS epidemic in the 1980s, there were no effective treatments against H.I.V., the virus that causes the disease. Because of this, many thousands of people died lingering deaths. The desperation of those times led to the rise of an activist movement that took to the streets and pressed government officials to expedite research on drugs to treat AIDS.
2014 Annual Report
May 29, 2015 – Progress in the Fight Against HIV, HCV, and TB.
TAG’s Involvement in HIV Cure Research
May 19, 2015 – A brief overview of TAG’s advocacy role in the pursuit of an HIV cure.
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
May 5, 2015, New York, New York – On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.
Governor Releases Blueprint to End AIDS in New York State by 2020
April 29, 2015, New York, New York – Governor Cuomo formally accepted the long-awaited Blueprint to End AIDS at a public event on Wednesday, marking an important step towards fulfilling his commitment to end AIDS in New York State.
Governor Cuomo’s Plan to End AIDS Will Save Lives and Money
April 21, 2015 – TAG & Housing Works Report Shows Plan to End AIDS by 2020 Will Translate into $4.5 Billion in Net Medicaid Savings for NY State.
- On Targets and Timelines
With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.
- Ending the HIV Epidemic (ETE) in New York State
Not only is it the right thing to do for the health of New Yorkers, but a new analysis demonstrates that it is also cost-effective.
- Toward an Ambitious National HIV/AIDS Strategy
We won’t end HIV as an epidemic with anemic goals, delayed surveillance data, feeble support of state policies and resource needs, and an inadequate implementation science agenda.
- An HIV Cure and a Vaccine within the Next 15 Years?
Optimism is not without merit, but the science remains incredibly fragile.
- C U L8ter: Hepatitis C Eradication
Hepatitis C is now curable. Now all we need is surveillance to monitor it, global funding to fight it, and targets set to address it.
- TB R&D’s Shift to the Left
As the Bill & Melinda Gates Foundation realigns its TB vaccine strategy to focus on early-stage candidate development, equitable access priorities must also be established before large-scale trials are conducted.
Guiding Principles for Eliminating Disease-Specific Criminal Laws
February 27, 2015 – The Positive Justice Project is dedicated to eliminating disease-specific criminal laws that base liability on an individual’s health status rather than on the intent to harm another individual. We oppose the use of felony laws, and the associated lengthy terms of incarceration that treat health status as evidence of wrongful intent, and transmission of a treatable illness as equivalent to manslaughter, vehicular homicide, and other forms of assaults that pose immediate, lifethreatening harm to another.
150 HIV Organizations Urge Continuation of D:A:D Study
February 20, 2015 – HIV drugs are used in combinations, so it is right that the companies who make and sell these drugs collaborate on this study on long-term safety.
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries (English and Russian)
February 2, 2015 – This report presents a number of key strategies through real-world case studies and shows how strategies used to combat the AIDS epidemic can be—and have been—adapted to increase HCV treatment access. These strategies are introduced in three sections: Laying the groundwork through community organizing; overcoming the cost barriers to HCV treatment access; and collaborating with researchers to build your case for HCV treatment access.
Governor Cuomo’s Ending the Epidemic Task Force Completes Plan to End AIDS in NY State by 2020
– Activists, service providers, public health professionals hail governor’s leadership, call on legislators and local governments to join forces to end the epidemic –
January 13, 2015, Albany, New York. Today the Ending the Epidemic Task Force, convened by the New York State Department of Health (DOH) at the behest of Governor Andrew M. Cuomo, completed its comprehensive, rigorous, and unprecedented plan to end AIDS in New York State by 2020.
December 15, 2014 – TAG’S PROGRESS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
- Letter from TAG Board Member Alby Maccarone
- Message from Board President Barbara Hughes
- TAG Catalyzes New York State’s Plan to End AIDS
- Reports from the Front
- Q&A with Kenyon Farrow, U.S. and Global Health Policy Director
- Q&A with Board Member Jim Aquino
2014 Symposium: Zero Accountability: When Action Doesn’t Match the Numbers (Video)
On October 30, 2014, in conjunction with the Union World Conference in Barcelona, Spain, Treatment Action Group (TAG), the Stop TB Partnership, Médecins Sans Frontières (MSF), Partners In Health (PIH), and the Harvard Medical School Department of Global Health and Social Medicine sponsored a symposium titled “Zero Accountability: when action doesn’t match the numbers.” The symposium began with an introduction highlighting inadequacies in the global response to the MDR-TB emergency. Two panels, with individual talks followed by panel-wide discussions, then convened around the current state of research and development for MDR-TB, including the complexity and duration of existing treatments, and key access issues, including pricing and the uptake of new drugs and regimens.
November 20, 2014 – Acclaimed pianist & composer Fred Hersch releases DVD of landmark jazz/theater piece, My Coma Dreams. Filmed live at Columbia University's Miller Theatre. Starring Actor/Singer Michael Winther with Fred Hersch & Ensemble. Released in honor of World AIDS Day; Proceeds to benefit TAG.
Activists Urge CDC Withdraw Ebola Travel Restrictions for Asymptomatic People
November 7, 2014 – We are concerned about the CDC allowance for public movement and assemblage restrictions for completely asymptomatic individuals in the “some-risk” exposure category. For this population, particularly those in compliance with direct active monitoring recommendations, such restrictions are de facto quarantines. There is no evidence to suggest that these restrictions provide any additional public health benefit.
Activists Urge Otsuka to Provide Access to TB Drug—Only a handful of patients have received Otsuka’s new drug, delamanid—
October 30, 2014, Barcelona, Spain – Tuberculosis (TB) activists interrupted Otsuka’s symposium at the 45th Conference on World Lung Health, calling for widespread registration of and immediate broad compassionate use access to delamanid, Otsuka’s new drug to treat multidrug-resistant TB (MDR-TB).
Advocates Urge Governor Cuomo to Withdraw Mandatory Quarantine Order
October 26, 2014 – We write as professionals, activists, and public health researchers who have worked to combat AIDS and other infectious diseases in New York and around the world for over three decades. We have not forgotten how HIV/AIDS was at first largely ignored while it appeared to affect only marginalized communities or the stigma generated once fear of the virus took hold in the larger population. We have watched with growing concern as Ebola virus disease (EVD) was ignored far too long while confined to some of the poorest countries in the world, and how it has now led to hysteria here in the United States, based on only a very small number of cases. As you know, stigma remains our biggest enemy in fighting AIDS and could quickly become the biggest barrier in combatting EVD. Therefore, we implore you to withdraw the mandatory quarantine requirement for all people entering the United States through Newark Liberty International Airport and John F. Kennedy International Airport who have had direct contact with individuals with EVD in Guinea, Liberia, and Sierra Leone.
Tuberculosis Research at Risk as Big Pharma Shutters Programs
October 22, 2014 – Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group (TAG). TAG’s ninth annual Report on Tuberculosis Research Funding Trends shows that the foundation of the TB research enterprise is shakier than ever, setting back efforts to fight a disease that in 2012 killed 1.3 million people and caused 8.6 million to fall sick.
Activists Urge Governor Cuomo to Reject Proposed NYS Medicaid HCV Treatment Restrictions
October 14, 2014 – As people living with or at risk for hepatitis C, their advocates, and care providers—and as New York State voters and taxpayers—we write to express our serious concerns about proposed Medicaid criteria that will limit access to sofosbuvir and other lifesaving hepatitis C medications. We urge you to reject these restrictive criteria and to support a comprehensive plan to end New York’s hepatitis C epidemic, as you have with HIV/AIDS.
NYS Ending the Epidemic Task Force
October 14, 2014, New York, New York – Treatment Action Group (TAG) welcomes today’s announcement by the New York State Department of Health (DOH) of the Ending the Epidemic Task Force to more fully develop Governor Andrew Cuomo’s plan to end AIDS as an epidemic in New York State by the year 2020.
- A Drug by Any Other Name
The basics of generic medications, bioequivalence, and the push for good manufacturing practices
Securing access to generic drugs to treat HIV, hepatitis C virus (HCV), and tuberculosis (TB) is now one of the most prominent strategies of global health care and treatment activism.
- The Road to Treatment Access
Generic drug registration, licensing, and a trip to Gilead’s islands
Access to essential medicines is part of the human right to health. But several steps are needed to create access to generics, including registration and licensing. Understanding these steps is critical for effective advocacy.
- Safeguarding against Stock-Outs
The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets
In the United States, where low-prevalence diseases like tuberculosis (TB) are at the mercy of limited market competition among generic drug makers, which can result in drug shortages when manufacturing or distribution problems arise.
- Generics vs. the Giant
For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable
As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced with the challenge of finding companion drugs to create regimens to which patients’ TB is still susceptible. For this reason, interest in procuring linezolid has been increasing.
Letters to Menigitis Vaccine Makers Urging Efficacy Studies in People with HIV
September 17, 2014 – Significant gaps in our knowledge base on the effectiveness of meningococcal vaccination with respect to preventing disease in people living with HIV make it more difficult to mount a strategic public health response to the outbreaks, both in New York City and other settings.
A Community Town Hall on HIV Cure Research in Washington, D.C.
On Tuesday, October 14th, 2014, please join us at an educational community town hall for HIV-positive individuals, advocates, providers and policymakers in the DC area interested in learning about the current status of research into curing HIV infection.
Two New Activist Guides on Delamanid and Linezolid
September 23, 2014 – Delamanid (also called Deltyba), the newest drug to fight tuberculosis (TB) was approved in Europe and Japan in 2014. An Activist’s Guide to Delamanid explains what we know about the drug’s efficacy and safety. Linezolid, an older drug important for treating some cases of drug-resistant TB, is being used more and more, and An Activist’s Guide to Linezolid summarizes the information we have on linezolid’s safety and efficacy in TB treatment. Both guides describe what activists—including people with TB, researchers, and doctors who treat TB—can do to help ensure access, fair pricing, and further research.
Advocacy Groups Report to UN on U.S. Failures to Address the HIV Epidemic in Communities of Color
August 14, 2014 – A national coalition of HIV/AIDS advocacy organizations has submitted a report to the United Nations in Geneva detailing the disparate impact of HIV/AIDS on communities of color, and identifying the lack of U.S. action on social drivers of the epidemic in those communities as a human rights violation. The report was produced by AIDS Foundation of Chicago (AFC), Center for HIV Law and Policy (CHLP), Counter Narrative Project, HIV Prevention Justice Alliance (HIV PJA), National Working Positive Coalition (NWPC), Positive Women’s Network of the United States of America (PWN-USA), Sero Project, Treatment Action Group (TAG), and Women with a Vision.
- Press release from the AIDS Foundation of Chicago.
- Complete report: HIV Criminalization, Poverty, and Health care Access – United States’ Violations of the International Convention on the Elimination of All Forms of Racial Discrimination.
Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
July 24, 2014, Melbourne, Australia – Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.” Their signs said, “Wanted: Crimes Against Access,” “Hep C Criminal,” and “Gilead Kills” as the O’Jay’s “For the Love of Money” blared in the background.
2014 Pipeline Report
July 20, 2014 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Visit www.PipelineReport.org to read the report online.
July 17, 2014 – TAG's staff and Board of Directors are at a loss for words following today's tragic downing of Malaysia Airlines Flight 17, made all the more horrific by the reported loss of several HIV/AIDS researchers, civil society staffers, and other community leaders en route to the International AIDS Conference in Melbourne. Our thoughts are with the families, friends, and colleagues of all 298 passengers and crew who perished.
First Hepatitis C Virus World Community Advisory Board Report
July 14, 2014 – The hepatitis C virus (HCV) World Community Advisory Board (CAB) grew from an international AIDS activist movement. The objectives of the meeting were threefold: 1. To provide a forum for leading activists to learn about developments in HCV treatment and access barriers; 2. To find common advocacy strategies; and 3. To meet with pharmaceutical companies about their plans for low- and middle-income countries (LMICs).
2013 Annual Report
July 11, 2014 – Progress in the Fight Against HIV, HCV, and TB.
Treatment Action Group Commends Governor Cuomo for Launching Historic New York State Plan to End AIDS
TAG Calls on Governor to Expeditiously Appoint a High-Level Task Force to Develop Blueprint to End AIDS Deaths and Halt New HIV Infections
June 29, 2014, New York, New York – Treatment Action Group (TAG) applauds Governor Andrew M. Cuomo for his full support of a historic community-developed plan to end the AIDS epidemic in New York State by 2020, as announced this morning by the Governor’s office and reported in today’s edition of the New York Times (“Cuomo Plan Seeks to End New York’s AIDS Epidemic,” Anemona Hartocollis, page A18). With this bold initiative, New York State—long the epicenter of the nation’s HIV epidemic—becomes the first jurisdiction anywhere in the world to publicly declare a goal of ending AIDS as an epidemic with the launch of a comprehensive effort to end AIDS deaths and halt new infections by employing state-of-the-art testing, preventive technologies, treatment, and supportive services.
ACT UP to Tom Frieden: You’re MIA on HIV
New Infections on the Rise in Key Subpopulations, Despite Options for Prevention
June 9, 2014 – Members of ACT UP/NY, along with Treatment Action Group (TAG) and Atlanta allies, will meet with the Centers for Disease Control and Prevention's (CDC's) HIV prevention personnel in Atlanta, Georgia. ACT UP will call upon the CDC to meet its commitment of keeping all Americans healthy and to act now upon the promise of TasP, PrEP, and PEP, address social and structural barriers to lifesaving prevention options, and reduce the transmission of HIV in those groups where the incidence is rising.
An Activist's Guide to Tuberculosis Drugs
May 29, 2014 – TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities. This guide provides a brief summary of safety and efficacy data for those drugs currently in use for TB (many of which have been approved for other diseases but are used off-label for TB), and suggests advocacy points for activists.
New Hepatitis Resolution Is Passed at World Health Assembly; Challenges World Health Organization and Member States to Act
May 22, 2014, Geneva, Switzerland – Today, four years after introducing its first viral hepatitis resolution, the World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—passed the Hepatitis Resolution, which commits the WHO and United Nations (UN) member states to urgent action to address the global hepatitis pandemic, including that of hepatitis C virus (HCV).
Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C
Position Paper for the 67th World Health Assembly, May 19–24, 2014
We, people living with HCV, HIV/AIDS, people who use drugs, and our advocates, urge United Nations (UN) Member States to act with urgency to end the hepatitis C epidemic; it is possible!
- Fool Us Once…
By Tim Horn
We’re being duped by our government agencies. We’re being hoodwinked by the Affordable Care Act (ACA). We’re being bamboozled by pharmaceutical companies and research networks. In this April Fools’ issue of TAGline, we highlight several missteps in research and policy that have required some degree of advocacy to remedy and ensure that the jokes don’t remain on us.
- Forgotten Negatives: The Limits of Treatment as Prevention
The CDC’s High-Impact Prevention strategy takes aim at the stubborn HIV incidence rate in the United States. The only problem: it doesn’t include an ambitious plan for those at risk for the virus
By Jeremiah Johnson
- The White House’s Fuzzy Math
An Office of National AIDS Policy progress report obscures the state of the domestic U.S. HIV/AIDS response
By Mark Harrington
- Marketplace Menaces: Discriminatory Practices by the ACA’s Qualified Health Plans
Advocates scramble to stay ahead of coverage rejections, formulary concerns, and exorbitant out-of-pocket expenses facing people living with HIV
By Kenyon Farrow
- Better Late Than Never: Efavirenz Dose Optimization
After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles
By Tim Horn and Polly Clayden
- Punked by Pharma: Public Funds for Private Products
Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?
By Lindsay McKenna
- Fool’s Errand: The Sloppy Science of the MDR-TB STREAM Trial
Confirming the efficacy and safety of bedaquiline-inclusive regimens is a priority. Comparing them to unvalidated MDR-TB drug combinations in the planned STREAM study is not the way to go about it
By Mike Frick
Falling Funding for Tuberculosis Research Threatens to Derail TB Elimination Efforts in the United States
Research Dollars Drop Just as Old Disease Grows More Difficult to Treat
March 24, 2014, Washington, D.C. – The goal of eliminating tuberculosis (TB) as a public health threat in the United States is under threat, a new policy brief released today by Treatment Action Group (TAG) shows. Analysis conducted by TAG reveals that spending on TB research and development (R&D) among U.S. government agencies declined from 2009 to 2012 in the face of budget instability, sequestration, and the rising costs of biomedical research.
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
February 28, 2014, Bangkok, Thailand – Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection that kills over 350,000 people each year.
Letter to Governor Cuomo on Ending AIDS in New York State
February 18, 2014, New York, New York – We write to follow-up on our January 14, 2014 letter regarding the development of a plan to end AIDS in New York State. In addition to creating a Task Force to End AIDS in New York to promptly develop a strategic blueprint and plan in collaboration with the community and the DOH AIDS Institute, we urge you to include the following items in your 30-day amendments to the 2014-2015 Executive Budget:
- $10 million in new funding for the AIDS Institute to implement the plan developed by the above noted task force;
- Article 7 language to eliminate the use of condoms as evidence of prostitution by police and prosecutors; and
- Article 7 language to legalize the possession of syringes.
Treatment Action Group mourns the death of TAG’s founding treasurer Marvin Shulman (May 17, 1932–January 15, 2014), who died Wednesday in Miami Beach, Florida. A beloved, compassionate, generous, and tireless AIDS activist, Marvin Shulman first joined the AIDS Coalition to Unleash Power (ACT UP)/New York at the time of its Wall Street II action on March 28, 1988, where he was arrested as a member of the ACT UP affinity group known as Wave 3. Marvin quickly became an active member of ACT UP/NY’s leadership, serving as ACT UP’s treasurer for several years.
2013 TAG Update
TAG’S PROGRESS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS
In this issue:
- Letter from Tom Duane
- Message from Board President Barbara Hughes
- TAG’s Progress Toward Revitalizing the National HIV/AIDS Strategy
- Working to Improve TB Care and Treatment among the Tibetan Community in Dharamsala, India
- Reports from the Front
- Politics Is a Major Hurdle in HIV Treatment
- Q & A with TB/HIV Project Officer Mike Frick
- Q & A with HIV Prevention Research & Policy Coordinator Jeremiah Johnson
- Q & A with Board Member Earl L. Plante
- Q & A with Board Member Frank Bua
CRAG, TAG Welcome Sanofi U.S. Commitment to Reduce the Price of Tuberculosis Drug Rifapentine
December 12, 2013 – The Community Research Advisors Group (CRAG) and Treatment Action Group (TAG) welcome the Sanofi U.S. decision to lower the price of the tuberculosis (TB) drug rifapentine to $32 per 32-tablet blister pack. The company indicates that the new price will become effective in January 2014 under 340(b) Public Health Service pricing.
Treatment Action Group Remembers Nelson Mandela
December 8, 2013 – Treatment Action Group salutes the achievements, life, legacy, and memory of Nelson R. Mandela, freedom fighter, prisoner at Robben Island, president of the African National Congress (ANC), from 1994 to 1999 South Africa’s first freely-elected President, and the man whose plea to his colleagues led to the establishment of South Africa’s public-sector HIV treatment program, now the world’s largest.
TAG Applauds $12 Billion Replenishment of Global Fund to Fight AIDS, Tuberculosis and Malaria, and Calls for Greater Flexibility to Support Middle-Income Countries Coping with Large HIV or TB Epidemics
December 3, 2013, New York, New York – Treatment Action Group applauds the donors who have helped make it possible to save more lives by raising a record-breaking $12 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years. TAG also commends the Obama administration for its generous match of one dollar for every two dollars contributed by other donors, which helped to drive up funding commitments in the current replenishment round.
167 Organizations and 513 Individuals Sign on to Letter to Secretary Sebelius on the Allowance of Co-pay Assistance in the ACA Health Plans
December 2, 2013 – We, the undersigned organizations and individuals, are writing to urge that the HHS issue clear guidance on the allowance of drug industry–provided co-payment, co-insurance, or other out-of-pocket discount cards and coupons in the Affordable Care Act’s (ACA) Health Insurance Marketplaces. As people living with, and organizations serving people with, HIV, HCV, and other life-threatening and chronic health conditions, we are alarmed by the possibility of the prohibition of these critical financial lifelines in the ACA, just as affordable health insurance for people with preexisting conditions is finally becoming a reality in the United States, thanks to the ACA.
amfAR and Treatment Action Group Call for a Strategic Research Agenda Needed to End HIV/AIDS in the United States
December 1, 2013, New York, New York – Today, on World AIDS Day, amfAR, The Foundation for AIDS Research, and Treatment Action Group (TAG) called for a deliberate and expedited research agenda designed to begin to end the AIDS epidemic in the United States. Both organizations noted that in order to achieve this goal, Congress must end sequestration and work to ensure the full implementation of the Affordable Care Act (ACA). AmfAR and TAG’s new report, Filling the Gaps in the U.S. HIV Treatment Cascade: Developing a Community-Driven Research Agenda, outlines several recommendations for the Obama administration.